Pharma Equity Group A/S

Pharma Equity Group A/S FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Pharma Equity Group A/S (PEG.CO) as of Oct 11, 2026 is 139.16 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 93.61 % — a change of 48.66% (higher).

FCF Conversion

139.16 %

YoY

48.66%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Pharma Equity Group A/S is 2025 139.16 % . FCF Conversion Rate (FCF/EBITDA) of Pharma Equity Group A/S was 2024 93.61 % . It decreases by 48.66% higher compared to the previous year.

The Pharma Equity Group A/S FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
20.47 DKK
Jan 1, 2019
16.12 DKK
Jan 1, 2020
30.13 DKK
Jan 1, 2021
-38.74 DKK
Jan 1, 2022
-82.61 DKK
Jan 1, 2023
67.85 DKK
Jan 1, 2024
93.61 DKK
Jan 1, 2025
139.16 DKK
The Pharma Equity Group A/S FCF Conversion history
YEARFCF ConversionYoY
139.16 %+48.66%
93.61 %+37.97%
67.85 %-182.13%
-82.61 %+113.23%
-38.74 %-228.59%
30.13 %+86.91%
16.12 %-21.26%
20.47 %-100.74%
-2,780.23 %-15,997.98%
17.49 %-83.49%
105.95 %+30.89%
80.94 %—
Access this data via the Eulerpool API
Get Free API Key

Pharma Equity Group A/S Stock analysis

What does Pharma Equity Group A/S do? Blue Vision A/S is a company specializing in the development, production, and marketing of underwater technology. It was founded in 1992 and is headquartered in Holstebro, Denmark. The company focuses on underwater lighting, underwater inspection cameras, and underwater communication. It specializes in manufacturing underwater lighting products for the offshore industry, ports, and shipping. It also produces underwater inspection cameras for inspecting underwater structures without the need for divers. In addition, the company has developed devices for underwater communication, which are crucial in the offshore industry and military sector. Blue Vision A/S emphasizes innovation and technology, holding patents and investing in digital technology to improve inspection systems. In summary, Blue Vision A/S specializes in underwater technology and offers solutions for the offshore industry, ports, and shipping. The company is committed to innovation and technology to provide the best solutions to its customers. Pharma Equity Group A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pharma Equity Group A/S stock

FCF Conversion Rate (FCF/EBITDA) of Pharma Equity Group A/S is 139.16 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Pharma Equity Group A/S changed from 93.61 % to 139.16 %, representing a 48.66% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Pharma Equity Group A/S since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Pharma Equity Group A/S with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API
Get Free API Key

Cash Flow — Pharma Equity Group A/S

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Pharma Equity Group A/S